

Hartmut Döhner

Name: Döhner
Given Name: Hartmut
Date of Birth: 17.08.1957

**Current positions**

- Medical Director, Department of Internal Medicine III (Hematology, Oncology, Palliative Medicine, Rheumatology, and Infectious Diseases), Ulm University Hospital, Ulm, Germany
- Deputy Director, Comprehensive Cancer Center Ulm (CCCU)
- Member, Scientific Executive Board, National Center of Tumor Diseases

ICKSH2022 Presentation Title

Towards precision medicine in AML

Education

1999 Professor of Medicine, Ulm University
1994 Postdoctoral Thesis (*Habilitation*), Internal Medicine, University of Heidelberg
1985 Doctoral Thesis (*Dr. med.*), Medicine, University of Freiburg

Professional Experiences

Since 2021 Deputy Director, Comprehensive Cancer Center Ulm
2006-2021 Director, Comprehensive Cancer Center Ulm
Since 2012 Coordinating Investigator, SFB 1074 'Experimental Models and Clinical Translation in Leukemia'
2014-2015 Vice President for Medicine and Diversity, Ulm University
2003-2011 Director, Department of Medicine, Ulm University
Since 1999 Professor of Medicine and Medical Director, Department of Internal Medicine III (Hematology, Oncology, Palliative Medicine, Rheumatology, and Infectious Diseases), Ulm University
1993-1999 Attending Physician (*Oberarzt*), Medizinische Klinik and Poliklinik V, University of Heidelberg
1988-1990 Post-doctoral Associate in the Division of Oncology (Prof. Clara D. Bloomfield), and the Division of Medical Genetics (Prof. Diane C. Arthur), University of Minnesota, Minneapolis, MN, USA
1985-1993 Training in Internal Medicine / Hematology/Oncology, Medizinische Klinik and Poliklinik V (Prof. W. Hunstein), University of Heidelberg
1983-1985 Residency in Surgical Pathology, Institute of Pathology, St. Vincentius-Krankenhäuser (Prof. H.M. Schneider, Dr. H. Wolfmüller), Karlsruhe

Main Scientific Publications

- Döhner H**, Wei A, Löwenberg B. Towards precision medicine for AML. **Nat Rev Clin Oncol.** 2021;18(9):577-590.
- Estey E, Hasserjian RP, **Döhner H**. Distinguishing AML from MDS: A fixed blast percentage may no longer be optimal. **Blood.** 2021 Jun 10:blood.2021011304. doi: 10.1182/blood.2021011304. Online ahead of print
- Wei AH, **Döhner H**, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Cakar MK, de Sousa AB, Rybka J, Frairia C, Borin L, Beltrami G, Cermak J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong

- Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators. Maintenance therapy with CC-486 for patients with acute myeloid leukemia in first remission after chemotherapy. *N Engl J Med.* 2020;383(26):2526-2537.
- DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, **Döhner H**, Letai AG, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hajek R, Porkka K, Egyed M, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW. Venetoclax and azacitidine combination for treatment-naïve patients with AML. *N Engl J Med.* 2020;383(7):617-629.
- Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, **Döhner H**. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. *N Engl J Med.* 2017;377(5):454-64.
- Gerstung M*, Papaemmanuil E*, Martincorena I, Bullinger L, Gaidzik VI, Paschka P, Heuser M, Thol F, Bolli N, Ganly P, Ganser A, McDermott U, Döhner K, Schlenk RF, **Döhner H***, Campbell PJ*. Precision oncology for acute myeloid leukemia using a knowledge bank approach. *Nat Genet.* 2017;49(3):332-40. *Equal contribution
- Döhner H**, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD. Diagnosis and management of acute myeloid leukemia in adults: 2017 ELN recommendations from an international expert panel. *Blood.* 2017;129(4):424-47.
- Papaemmanuil E*, Gerstung M*, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gündem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Döhner K, Schlenk RF, **Döhner H***, Campbell PJ*. Genomic classification and prognosis in acute myeloid leukemia. *N Engl J Med.* 2016;374(23):2209-21. *Equal contribution
- Döhner H**, Weisdorf D, Bloomfield CD. Acute myeloid leukemia (review). *N Engl J Med.* 2015;373(12):1136-52.
- Schlenk RF*, Döhner K*, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A*, **Döhner H***, for the German-Austrian AML Study Group (AMLSSG). Mutations and outcome of treatment in cytogenetically normal acute myeloid leukemia. *N Engl J Med.* 2008;358(18):1909-18. *Equal contribution.
- Bullinger L, Döhner K, Bair E, Fröhling S, Schlenk R, Tibshirani R, **Döhner H**, Pollack JR. Use of gene expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. *N Engl J Med.* 2004;350(16):1605-16.
- Döhner H**, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P. Genomic aberrations and survival in patients with chronic lymphocytic leukemia. *N Engl J Med.* 2000;343(26):1910-16.